Over two-thirds of biopharmaceutical manufacturers now report that their facility is experiencing capacity bottlenecks due to downstream processing. A number of factors continue to converge to create ...

Making a therapeutic that contains biological components is just the start of creating a medicine. Then, biopharmaceutical companies must capture that drug and ensure that it’s free of contamination.

FUJIFILM Biotechnologies introduces ShunzymeX precision purification technology for downstream processing of complex biologics: Teessid, United Kingdom Thursday, March 5, 2026, 16 ...

Creative Biolabs announces upgraded downstream services designed to bridge the gap between raw antibody expression and advanced preclinical development. SHIRLEY, NY ...